News

Public · Published

enVVeno Medical to Showcase the enVVe System at 38th Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium

enVVeno Medical announced that CEO Rob Berman will present its investigational enVVe System at the 38th annual Transcatheter Cardiovascular Therapeutics symposium in San Diego on November 2, 2026. His talk will introduce the system, a proposed transcatheter replacement venous valve, to cardiovascular specialists.

Published:

Updated:

What happened

enVVeno Medical announced that CEO Rob Berman will present its investigational enVVe System at the 38th annual Transcatheter Cardiovascular Therapeutics symposium in San Diego on November 2, 2026. His talk will introduce the system, a proposed transcatheter replacement venous valve, to cardiovascular specialists.

Confirmed

Global impact / market context

The presentation gives enVVeno a chance to explain its device to specialists and investors at a large medical meeting. If interest eventually supports further development or use, that could help the company pursue revenue, but the article reports no clinical results, regulatory clearance, sales, or financing.

Analyst inference

The article frames deep venous disease as an unmet medical need and describes the enVVe System as investigational, meaning it is still under evaluation. A conference presentation is a visibility event, not evidence that the device works, has approval, or is commercially available.

Analyst inference

What to watch

  1. Watch for details from Berman’s November 2 presentation, especially any evidence about the device’s potential role in treating deep venous disease beyond the announced introduction. Analyst inference
  2. Look for subsequent clinical findings or regulatory updates; the supplied article provides neither results nor an approval decision for the investigational enVVe System. Analyst inference
  3. Assess whether specialist or investor interest leads to concrete development steps, such as additional studies, because such work could require company spending before revenue. Analyst inference

Evidence